Single-center retrospective study of thromboembolic complications in Grade II–IV gliomas

Takeaway

  • The risk of venous thromboembolism (VTE) is increased in patients with Grades II–III glioma compared with the general population, and the risk of VTE is decreased in the presence of an isocitrate dehydrogenase (IDH) mutation.

Why this matters

  • VTE is a known complication of glioblastoma (Grade IV), but the incidence of VTE in lower-grade gliomas (Grade II–III) is not well established.

  • Classification of gliomas has now incorporated genetic information (as per WHO guidelines) and there has been a growing interest in evaluating the association of genetic subtypes with clinical characteristics.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.